Radical prostatectomy specimens from 53 men with clinical stage A or B prostate cancer were retrospectively reviewed and compared with correlative axial T2-weighted magnetic resonance (MR) images obtained just before surgery. Non-cancerous lesions were evaluated for signal intensity and location. Focal high-signal-intensity areas (n = 72) were present in 81% of patients. The 26% of lesions seen in the central gland all correlated with cystic atrophy. Of the 53 lesions seen in the peripheral prostate, 47 (89%) were cystic atrophy without associated cancer, four (7.5%) cystic atrophy with cancer, and two (3.8%) focal inflammation. Focal low-signal-intensity areas (n = 42) were present in 60% of patients. Of the 31% of lesions in the central prostate, one-fifth correlated with benign prostatic hyperplasia (BPH) and four-fifths with fibrous tissue. Of the 69% of peripheral lesions, 83% corresponded to fibrous tissue, 10% to BPH, and 7% to normal tissue. Mixed lesions (n = 42) were present in 64% of patients; 86% of these were located centrally and 14% peripherally. All mixed central lesions were BPH; the peripheral lesions were areas of combined cystic atrophy and fibrosis. BPH of low or mixed signal intensity can extend into the peripheral prostate and mimic cancer. High-intensity cystic atrophy associated with cancer can mimic normal tissue.

No abstract

To investigate the magnetic resonance (MR) imaging findings of hepatic cirrhosis and the potential of MR imaging in differentiating cirrhosis from other hepatic abnormalities, three observers with different levels of expertise in MR imaging (specialist, experienced radiologist, and novice with special training) reviewed hepatic MR imaging examinations of 52 patients with biopsy-proved presence (n = 29) or absence (n = 23) of cirrhosis. All examinations included motion-compensated T1-weighted, T2-weighted, and flow-sensitive gradient-echo images. For all three observers, linear signal irregularity was more accurate than other findings. For the final diagnosis of cirrhosis, the specialist was most sensitive (76% at high threshold, 97% at low threshold), followed by the novice with special training (31% and 79%, respectively). Specificity was 100% for all observers at high threshold and 78%, 96%, and 87% for expert, experienced, and trained novice observers, respectively, at low threshold. Sensitivity did not vary regardless of severity of fibrosis, as determined independently by a hepatopathologist. MR imaging has the potential of offering a comprehensive noninvasive evaluation of patients with suspected cirrhosis, but considerable expertise is required at present.

Interstitial lung disease (ILD) is a progressive fibrotic disease associated with rheumatoid arthritis (RA); real-world data for evaluating RA–associated ILD (RA–ILD) are limited. We evaluated prevalence, time to onset, clinical characteristics and prognostic factors in patients diagnosed with RA (n = 8963) in the Discus Analytics JointMan database (2009–2019) with and without ILD. ILD prevalence was 4.1% (95% confidence interval 3.7–4.5); > 90% had an ILD diagnosis after RA diagnosis (mean time to onset 3.3 years). At baseline, a higher proportion of patients with RA–ILD were older (> 65 years), male, with history of chronic obstructive pulmonary disease (COPD) compared with patients in the RA cohort. Patients in the RA–ILD cohort were likely to have more severe RA characteristics and joint evaluation compared with patients without ILD, at baseline and before/after ILD diagnosis. In this large, real-world database patients with (vs without) ILD had a higher burden of RA characteristics. Previously established risk factors for RA–ILD were confirmed (age, baseline COPD, anti-cyclic citrullinated peptide positivity, C-reactive protein, Clinical Disease Activity Index score); thus, recognition of these factors and tracking routine disease activity metrics may help identify patients at higher risk of RA complications and lead to improved diagnosis and earlier treatment.